Sara Thomas Rosen

Affiliations: 
1989 Department of Linguistics Kansas University  
Google:
"Sara Rosen"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Martinez XU, Chowdhury A, Stiller T, et al. (2021) The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Buettner R, Nguyen LXT, Morales C, et al. (2021) Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. Journal of Hematology & Oncology. 14: 70
Cao X, Li B, Chen J, et al. (2021) Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. Journal For Immunotherapy of Cancer. 9
Bennett CL, Hoque S, Olivieri N, et al. (2021) Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). Eclinicalmedicine. 31: 100693
Gunes EG, Rosen ST, Querfeld C. (2020) The role of myeloid-derived suppressor cells in hematologic malignancies. Current Opinion in Oncology
Han Z, Rosen ST, Querfeld C. (2020) Targeting microRNA in hematologic malignancies. Current Opinion in Oncology
Nathwani N, Palmer J, Synold TW, et al. (2020) Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia
Lansigan F, Horwitz SM, Pinter-Brown LC, et al. (2020) Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma, Myeloma & Leukemia
Di Raimondo C, Parekh V, Song JY, et al. (2020) Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review. Current Hematologic Malignancy Reports
Chen R, Herrera AF, Hou J, et al. (2019) Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
See more...